Recombinant Equine PDGF-BB Protein

Catalog #: 8585-BB Datasheet

Carrier Free

Catalog #	Availability	Size / Price	Qty
8585-BB-010/CF

With Carrier

Catalog #	Availability	Size / Price	Qty
8585-BB-010

R&D Systems Recombinant Proteins and Enzymes

1 Image

All PDGF-BB Proteins and Enzymes

Product Details

FAQs

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Equine PDGF-BB Protein Summary

Product Specifications

Purity

>95%, by SDS-PAGE with silver staining

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured in a cell proliferation assay using NR6R‑3T3 mouse fibroblast cells. Raines, E.W. et al. (1985) Methods Enzymol. 109:749. The ED₅₀ for this effect is 5-30 ng/mL.

Source

E. coli-derived equine PDGF-BB protein
Ser51-Thr159

Accession #

XP_005606703

N-terminal Sequence
Analysis

Ser51

Structure / Form

Disulfide-linked homodimer

Predicted Molecular Mass

12 kDa

SDS-PAGE

12 kDa, reducing conditions

Product Datasheets

8585-BB (with carrier)

Product Datasheet

8585-BB/CF (carrier free)

Product Datasheet

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

8585-BB

Formulation	Lyophilized from a 0.2 μm filtered solution in HCl with BSA as a carrier protein.
Reconstitution	Reconstitute at 100 μg/mL in 4 mM HCl.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

8585-BB/CF

Formulation	Lyophilized from a 0.2 μm filtered solution in HCl.
Reconstitution	Reconstitute at 100 μg/mL in 4 mM HCl.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: PDGF-BB

Platelet-Derived Growth Factor (PDGF)-BB is synthesized as a prepro-precurser that contains a signal peptide, an N-terminal prodomain, a mature region, and a
C-terminal prodomain (1-4). The proprecursor is initially dimerized and then intracellulary processed twice. The N-terminal prodomain is cleaved first, followed by cleavage of the C-terminal prodomain prior to the formation of a disulfide-linked homodimer. Mature equine PDGF-B shares 95%, 88%, 89%, 83%, 79%, and 79% amino acid sequence identity with human, mouse, rat, sheep, cow, and goat PDGF-B, respectively. PDGF-BB is expressed by hepatocytes and nonresorbing osteoclasts, generating osteoblasts and bone formation (4, 5). It is also produced by platelets, macrophages, and mast cells. At sites of injury, it promotes neutrophil and macrophage infiltration for debridement, fibroblast secretion of new extracellular matrix, and IGF-I-mediated re-epithelialization (6, 7). The traditional receptor for PDGF is either a homodimer or heterodimer created from two type I transmembrane RTKs, PDGF R alpha and PDGF R beta (8, 9). PDGF-BB has been shown to bind the alpha alpha homodimer, alpha beta heterodimer, and the beta beta homodimer in vitro, and act through the beta beta homodimer in vivo (8, 10). Equine PDGF-BB has been shown to stimulate contraction of fibroblast-populated collagen matrix, a model of equine wound contraction, in a Rho kinase- and p38-dependent manner (12). PDGF-BB is present in platelet-rich plasma (PRP), which has been used to treat soft tissue injuries in horses (13, 14). The levels of equine PDGF-BB in PRP is dependent on breed, gender, and age (15).

References